

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

SW1736

RRID:CVCL_3883

Type: Cell Line

Proper Citation

RRID:CVCL_3883

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3883

Proper Citation: RRID:CVCL_3883

Description: Cell line SW1736 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Thyroid gland anaplastic carcinoma

Defining Citation: [PMID:3518877](#), [PMID:6220172](#), [PMID:14522906](#), [PMID:17465858](#), [PMID:18713817](#), [PMID:21868764](#), [PMID:23833040](#), [PMID:24825855](#), [PMID:25365311](#), [PMID:26958598](#), [PMID:30737244](#)

Comments: From: Scott and White Clinic; Temple; USA.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SW1736

Synonyms: SW-1736, SW 1736

Cross References: BTO:BTO_0001611, EFO:EFO_0022676, cancercellines:CVCL_3883, ChEMBL-Cells:ChEMBL3307699, ChEMBL-Targets:ChEMBL614773, CLS:300453, Cosmic:886549, Cosmic:1068627, Cosmic:1239961, Cosmic:1280048, Cosmic:1507375, Cosmic:1533551, Cosmic:1536128, Cosmic:1889006, Cosmic:2050366, Cosmic:2054081, Cosmic:2319853, Cosmic:2786689, Cosmic:2791084, IARC_TP53:27015, IBRC:C10311, PubChem_Cell_line:CVCL_3883, Wikidata:Q29964497

ID: CVCL_3883

Record Creation Time: 20220427T221615+0000

Record Last Update: 20260905T182522+0000

Ratings and Alerts

No rating or validation information has been found for SW1736.

No alerts have been found for SW1736.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Cirello V, et al. (2025) TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer. The Journal of clinical endocrinology and metabolism.

Lim G, et al. (2025) AURKB and PI3K/AKT/mTOR pathways converge to regulate TERT expression. iScience, 28(8), 113194.

Xu Y, et al. (2024) BRAF-induced EHF expression affects TERT in aggressive papillary thyroid cancer. The Journal of clinical endocrinology and metabolism.

Hicks HM, et al. (2024) The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. Cancer biology & therapy, 25(1), 2332000.

Henderson YC, et al. (2021) A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma. The Journal of clinical endocrinology and metabolism, 106(10), 2962.

Marlow LA, et al. (2018) Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts. The Journal of clinical endocrinology and metabolism, 103(9), 3169.